A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Columbia University Medical Center, New York

University of Pittsburgh Cancer Institute, Pittsburgh

Fox Chase Cancer Center, Philadelphia

Virginia Cancer Specialists, Fairfax

Mount Sinai Comprehensive Cancer Center, Miami Beach

Sarah Cannon Research Institute, Nashville

University Hospital of Cleveland, Cleveland

Karmanos Cancer Institute, Detroit

Henry Ford Health System, Detroit

University of Iowa Hospitals and Clinics, Iowa City

University of Kansas Cancer Center, Fairway

Mary Crowley Research Center, Dallas

Huntsman Cancer Institute, Salt Lake City

Honor Health Research Institute, Scottsdale

Cedars-Sinai Medical Center, Los Angeles

University of California Los Angeles, Los Angeles

University of California, San Francisco, San Francisco

University of California, Davis, Sacramento

Medical College of Wisconsin, Milwaukee

Site CA15004, Edmonton

Site CA15003, Toronto

Site CA15001, Toronto

Site CA15002, Montreal

Site IT39004, Ancona

Site IT39002, Milan

Site IT39003, Milan

Site IT39008, Milan

Site IT39009, Milan

Site IT39010, Modena

Site IT39005, Monza

Site IT39011, Negrar

Site JP81001, Chūōku

Site PT35101, Lisbon

Site PT35106, Porto

Site KR82006, Seoul

Site ES34002, Barcelona

Site ES34003, Barcelona

Site ES34009, Barcelona

Site ES34010, Barcelona

Site ES34001, Madrid

Site ES34006, Madrid

Site ES34013, Madrid

Site ES34014, Valencia

Site TW88601, Tainan City

Site TW88603, Taipei

Site GB44003, London

Site GB44006, London

Site GB44004, Newcastle upon Tyne

Site GB44005, Sutton Surry

Site KR82004, Goyang-si

Site KR82005, Seongnam-si

Site KR82001, Seoul

SIte KR82002, Seoul

Site TW88602, Taichung